Archive: January 01 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Comparing efficacy outcomes of ide-cel versus conventional care in R/R myeloma
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses an analysis that compared efficacy outcomes seen in the MAMMOTH study, a retrospective observational study of conventional care regimens, and the KarMMA trial (NCT03361748) of the BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel), both in triple-class refractory multiple myeloma patients.
DARAZADEX: a Phase II trial of daratumumab plus azacitidine and dexamethasone in...
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, shares the details of an ongoing Phase II trial (NCT04407442) of daratumumab, an anti-CD38 monoclonal antibody, in combination with azacitidine and dexamethasone in relapsed/refractory (R/R) multiple myeloma patients.